Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate.

Headed by president and CEO Niall O’Donnell (pictured), the San Diego-based company launched last year with $50 million and an investigational small molecule drug it licensed from High Point, NC-based vTv Therapeutics (NASDAQ: VTVT).

The molecule, REN001, is being developed for patients with primary mitochondrial myopathies (PMM). Muscle cells use the energy generated by mitochondria to function, and when that… Read more »